Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2025 08:53 ET | Source: Research and Markets

Neurological Biomarkers: Global Market Review 2020-2024 and Forecast to 2030, Featuring Analysis of PerkinElmer, Abbott Labs, Thermo Fisher Scientific, Banyan Biomarkers, Bio-Rad Labs & More

Dublin, March 11, 2025 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
February 27, 2025 16:15 ET | Source: Alumis Inc.

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases
October 24, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
September 26, 2024 06:02 ET | Source: Research and Markets

Precision Neurodegenerative Disease Global Market Report 2024-2028: Key Growth Opportunities in GLP-1 RA and Insulin for AD and PD Patients and Neurotech-based Precision Therapies

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Precision Neurodegenerative Disease Market, Global, 2024-2028" report has been added to ResearchAndMarkets.com's offering.The rising global...
August 14, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
August 01, 2024 04:46 ET | Source: Research and Markets

Molecular Diagnostics for Neurodegenerative Diseases Technology Research Report 2024-2028 Featuring Synaps Dx, AgenT Biotech, Urvogelbio, Resonant, and Neurodex

Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028" report has been added to ResearchAndMarkets.com's...
July 31, 2024 09:00 ET | Source: Vaccinex, Inc.

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

Positive data for SIGNAL-AD trial of Pepinemab in Alzheimer’s Disease affirm expectation of a novel mechanism to delay progression of Alzheimer’s disease
March 28, 2024 17:56 ET | Source: Research and Markets

United States Frontotemporal Dementia Market to Experience Steady Growth Through 2028

Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "United States Frontotemporal Dementia Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...
February 15, 2024 10:38 ET | Source: OrphAI Therapeutics Inc.

OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union

GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
February 12, 2024 07:10 ET | Source: DataHorizzon Research

Neurodegenerative Disease Market Size To Reach USD 96.4 Billion By 2032 | DataHorizzon Research

Fort Collins, Colorado, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Neurodegenerative Disease Market size was valued at USD 51.2 Billion in 2023 and is anticipated to reach USD 96.4 Billion by 2032 at a...

Next Page keyboard_arrow_right